|
| Exchange Disseminated Time | Aventis Pharma Ltd has informed BSE that the members at the Annual General Meeting (AGM) of the Company held on April 27, 2010, inter alia, have accorded to the following:
1. Adoption of the Accounts for the year ended December 31, 2009 being the Balance Sheet as at December 31, 2009 and the Profit and Loss Account for the year ended on that date with the Auditors’ Report and the Report of the Directors.
2. Confirmation of Interim Dividend for the year ended December 31, 2009 of Rs. 3.50 per Equity Share of Rs. 10 & final dividend for the year ended December 31, 2009 of Rs. 16.50 per Equity Share of Rs. 10.
3. Re-appointment of Mr. A. K. R. Nedungadi & Mr. J.M. Gandhi as Directors of the Company.
4. Appointment of M/s. S. R. Batliboi & Co., Chartered Accountants as Auditors of the Company to hold office from the conclusion of this Meeting till the conclusion of the next Annual General Meeting of the Company, on remuneration, terms & conditions.
5. Appointment of Mr. M. Dargentolle (presently an Alternate to Mr. O. Charmeil) as Wholetime Director of the Company for a period of five years from October 27, 2009 and to his receiving remuneration, benefits and amenities as Wholetime Director of the Company upon the terms and conditions and stipulations contained in an agreement to be entered into between the Company and Mr. Dargentolle, a draft whereof is placed before the Meeting and, for the purposes of identification is initialed by the Chairman of the Meeting. Provided that the aforesaid approval and consent shall not be impaired by reason of Mr. Charmeil returning to the State of Maharashtra and Mr. Dargentolle being appointed as an Alternate Director to Mr. Charmeil or Mr. Dargentolle being appointed as Alternate Director to any other Director or Mr. Dargentolle filling in any casual vacancy or being appointed as Additional Director or as a Director in his own right by the Company in General Meeting.
6. The Companies Act, 1956, the Company’s Directors other than the Managing Director or Wholetime Directors or Directors who are employees of sanofi-aventis Group Companies, in addition to sifting fees paid to them for attending the Meetings of the Board of Directors or its Committees, be paid every year for a period of five years from January 01, 2009, commission of an amount as may be determined by the Board of Directors from time to time, subject to a ceiling of one per cent of the net profits of the Company computed in the manner laid down in Section 198(1) of the Companies Act, 1956, with authority to the Board of Directors to distribute the commission amongst such Directors in such manner as the Board of Directors may from time to time decide. |
|
|